Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2021-09-10 Regulatory Filings
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
TheraVet annonce le lancement de l’étude clinique pivot multicentrique européenne évaluant VISCO-VET dans l’arthrose canine
Regulatory Filings Classification · 95% confidence The document is a press release from TheraVet announcing the launch of a clinical trial for their product VISCO-VET. It provides details on the study design, regulatory status, and expected timelines. As it is a general corporate announcement regarding business operations and clinical progress that does not fit into specific categories like financial reports or shareholder voting, it is classified as a Regulatory Filing (RNS).
2021-09-10 French
TheraVet kondigt de lancering van de pivotale Europese multicentrische klinische studie met VISCO-VET tegen artrose bij honden aan
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Persbericht - Inside-informatie - Gereglementeerde informatie" (Press Release - Inside Information - Regulated Information). It announces the launch of a clinical study for a product called VISCO-VET, providing key operational updates (approvals, start dates, patient numbers). This format, focusing on a specific, material, non-financial operational event announced via a press release, aligns best with a general regulatory announcement that doesn't fit the more specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS). Since it is a formal, regulated announcement that doesn't fit the other specific categories, the most appropriate classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2021-09-10 Dutch
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 10, 2021, announcing the launch of a pivotal European multicentric clinical study for a product called VISCO-VET in canine osteoarthritis. It details the study's design, countries involved, and expected timelines for patient enrollment and results updates. This type of announcement, detailing operational progress, clinical trials, and future reporting schedules, is characteristic of general corporate news releases that do not fit into specific financial reporting categories like 10-K, ER, or IR. Since it is a general corporate announcement that doesn't fit the specific definitions (like M&A, Capital Change, Dividend, or Director Dealing), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory or significant corporate announcements not covered elsewhere.
2021-09-10 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 10, 2021, announcing the launch of a pivotal European clinical study for a product called VISCO-VET to treat canine osteoarthritis. It details the study design, countries involved, and timelines for patient recruitment and results updates. This type of announcement, which communicates significant operational or clinical development news to the market, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but since it is a standalone operational update about a clinical trial launch, RNS is the most appropriate general category for non-standard announcements. It is not a full financial report (10-K, IR), a management change (MANG), or a dividend notice (DIV). Given the context of a biotech company announcing a major clinical trial milestone, RNS serves as the best fit among the provided options for a general regulatory/operational announcement.
2021-09-10 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is a press release announcing positive safety and efficacy results from a Proof-of-Concept (PoC) clinical study for a product called VISCO-VET in canine osteoarthritis. It details study objectives, statistical outcomes (p-values, percentage improvements), and includes quotes from the Principal Investigator and the CEO. This type of announcement, focusing on clinical trial results and product development milestones, is typically classified as an Earnings Release (ER) if it accompanies periodic financial results, or sometimes as a Regulatory Filing (RNS) if it's a general corporate update not fitting other specific categories. However, since it is a specific announcement of clinical trial success, which often drives investor interest and is sometimes released alongside or instead of a formal earnings report, it fits best under the general category for significant corporate news that isn't a formal financial statement (like 10-K or IR). Given the options, and since it is a direct announcement of operational/clinical progress rather than a formal financial report, Earnings Release (ER) is often used for such material updates, or RNS as a general regulatory announcement. Since it is not a transcript (CT), a formal financial report (10-K, IR), or a presentation (IP), and it is a material announcement, I will classify it as an Earnings Release (ER) as these often contain operational highlights that drive market reaction, or RNS as a general announcement. Given the content is purely clinical/operational news, RNS is the safest general category for material, non-financial-statement announcements, but ER is often used for positive/negative trial results announcements. I will lean towards ER as it functions as a major operational update that impacts future earnings potential, similar to how preliminary results are often released. However, looking closely at the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, it is a material corporate announcement that doesn't fit the specific financial or governance categories. It is best classified as a Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements. FY 2021
2021-09-08 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 8, 2021, announcing positive safety and efficacy results from a proof-of-concept clinical study for a product called VISCO-VET in canine osteoarthritis. It details clinical endpoints (mobility, pain reduction) and compares results to current treatments. This type of announcement, focusing on clinical trial outcomes and product development milestones, is typically classified as an Earnings Release (ER) if it's a summary of period results, or sometimes as Regulatory Filings (RNS) if it's a general update. However, since it is a specific announcement of clinical trial results which are key operational/financial drivers, and it is not a full financial report (like 10-K or IR), it fits best under the general category for operational/business updates that aren't explicitly covered elsewhere. Given the options, and since it's a press release detailing operational/R&D progress rather than a formal financial statement or a transcript, it most closely aligns with an Earnings Release (ER) which often includes operational highlights, or RNS as a general regulatory/news announcement. Since it is not a formal earnings report summary but a specific clinical update, RNS (Regulatory Filings/General Announcement) is a strong candidate, but ER often encompasses press releases about key operational achievements like successful trials. Given the context of financial reporting databases, press releases announcing significant operational milestones (like positive trial data) are frequently categorized as ERs or RNS. I will choose ER as it relates to performance indicators, but RNS is also plausible. Given the content is purely scientific/clinical results announcement, RNS is the safer general news category if ER is reserved strictly for quarterly/annual financial summaries. Since the document mentions a 'Prochain rendez-vous financier' (Next financial appointment) for 'Résultats semestriels' (Half-year results), this specific document is likely *not* the formal Earnings Release itself, but rather a news release. Therefore, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a significant, non-standard operational press release.
2021-09-08 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.